[Verified Answer]: In the NO-AD trial (introduced in question…

In the NO-AD trial (introduced in question 3), 692 participants were randomized to receive either placebo or 250 mg of a tree-derived carbohydrate that targets beta-amyloid twice per day. Some of the inclusion and exclusion criteria are listed below: Inclusion Criteria: Aged 50-85 years Meet diagnostic criteria of mild-to-moderate Alzheimer’s disease Subjects should have stable, reliable caregivers, or at least have frequent contact with caregivers (at least 4 days every week, at least 2 h every day). Exclusion Criteria: Dementia due to other causes Other nervous system disorders (including stroke, optic neuromyelitis, Parkinson’s disease, epilepsy) Laboratory values indicative of abnormal liver function, kidney function, sugar levels, clotting, or blood cell counts Unstable or severe cardiac, pulmonary, hepatic, renal or hematopoietic disease At 36 weeks, subjects taking the investigational drug showed an average improvement of 2.63 relative to placebo on the ADAS-cog scale, which measures patients’ cognitive impairment on a range from 0 to 70. This difference was statistically significant. The drug was found to be safe and well-tolerated with respect to major adverse events versus placebo. For which special pathway or pathways could this drug be eligible? Indicate all that could apply. Priority Review 2. Breakthrough Therapy 3. Accelerated approval 4.Fast track 5. Orphan drug